Smithers Avanza, a contract research organization (CRO) supporting the pharmaceutical industry, announced that its Bioanalytical Services Division has Clinical Laboratory Improvement Amendments (CLIA) certification.
“Our clients’ requirements for independent, third-party testing expertise differ from phase to phase in their clinical trials,” said Ira DuBey, Executive Vice President, Bioanalytical Services Division, Smithers Avanza. “Obtaining CLIA certification verifies that we are a trusted laboratory resource throughout the drug development process, providing the right service and phase-appropriate expertise at the right moments for our clients.”
CLIA certification is overseen by the Centers for Medicare and Medicaid Services (CMS) and is mandatory for any laboratory performing testing that leads to the diagnosis or health assessment of patients.
For more information about the Smithers Avanza portfolio of services, visit http://smithersavanza.com.
# # #
About Smithers Avanza
Smithers Avanza is a contract research organization (CRO) supporting the pharmaceutical industry. Our scientists have expertise in large molecule bioanalysis, assay development, validation, and specimen analysis at our GLP- and GCP-compliant and CLIA-certified laboratory. Smithers Avanza Bioanalytical Services Division supports the development of biologics and vaccines from discovery through phase IV, with expertise that includes bioassays and high sensitivity assays. The services focus primarily on development, validation, and specimen analysis for PK/TK, ADA, bioassays, and biomarker assays. Smithers Avanza also offers preclinical toxicology and vaccine testing at our AAALAC accredited facilities.